Tavapadon met the primary endpoint in the pivotal Phase 3 TEMPO-2 flexible-dose monotherapy trial, demonstrating a statistically significant improvement from baseline in the MDS-UPDRS Parts II and III ...
J.P. Morgan 2025 Healthcare Conference, taking place January 13–16, 2025, in San Francisco, CA ...
New research suggests Alzheimer's drugs may improve cognition by increasing Aβ42 levels rather than just reducing plaques, ...
Bobbi Conner talks with MUSC's Dr. Vanessa Hinson about what causes Parkinson’s disease and what can be done to reduce the ...
A study from the University of Arizona shows that the protein PNA5 helps protect brain cells, offering a promising avenue for treating cognitive symptoms in Parkinson’s disease, a condition currently ...
BioArctic begins patient dosing in EXIST phase 2a study in Parkinson’s disease: Stockholm Saturday, December 7, 2024, 18:00 Hrs [IST] BioArctic AB (publ), a Swedish research-bas ...
A new laboratory study in mice suggests that primates like humans evolved large brains with a helping hand from microbes that ...
The new Marie Skłodowska-Curie Doctoral Network AIPD is dedicated to investigating artificial intelligence methods to combat Parkinson's disease. It ...
The lab of Hassane Mchaourab, director of the Center for Applied Artificial Intelligence in Protein Dynamics and professor of ...
The company is hoping to show GT-02287 can slow Parkinson's progression by restoring function of GCase, an enzyme encoded by ...
Pooled data analysis of efficacy and safety from Phase 2b and Phase 3 data sets in patients with early-stage Parkinson’s ...
SOUTH SAN FRANCISCO, Calif., Dec. 05, 2024 (GLOBE NEWSWIRE) -- (Nasdaq: DNLI) today announced initiation of dosing in a global Phase 2a clinical study, BEACON, of the investigational drug ...